Anti-TNF biosimilars in rheumatology: the end of an era?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Anti-TNF biosimilars in rheumatology: the end of an era?

Published:2020-08-12 Issue:1 Volume:21 Page:29-36
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Dey Mrinalini¹²,Zhao Sizheng Steven¹²,Moots Robert J.²³

Affiliation:

1. Institute of Life Course and Medical Sciences, University of Liverpool, 3rd Floor Clinical Sciences Centre, Aintree Hospital, Liverpool, UK

2. Department of Rheumatology, Aintree Hospital, Liverpool University Hospitals NHS Foundation Trust Liverpool, UK

3. Faculty of Health, Social Care and Medicine, Edge Hill University Ormskirk, UK

Funder

not funded

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2020.1802421

Reference67 articles.

1. Evolution of treatment for rheumatoid arthritis

2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

3. BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics

4. Early Recognition and Treatment Heralds Optimal Outcomes: the Benefits of Combined Rheumatology–Dermatology Clinics and Integrative Care of Psoriasis and Psoriatic Arthritis Patients

5. Early Recognition and Treatment Heralds Optimal Outcomes: the Benefits of Combined Rheumatology–Dermatology Clinics and Integrative Care of Psoriasis and Psoriatic Arthritis Patients

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor Necrosis Alpha (TNF-α) Antagonists Used in Chronic Inflammatory Rheumatic Diseases: Risks and their Minimization Measures;Current Drug Safety;2024-11

2. Histoplasmosis around the world: A global perspective on the presentation, virulence factors, and treatment of histoplasmosis;The American Journal of the Medical Sciences;2024-10

3. Physicians’ and patients’ perception of biosimilars and factors affecting biosimilar prescribing in selected Asian Countries: a survey study;Expert Opinion on Biological Therapy;2024-09-05

4. Cancer treatment with biosimilar drugs: A review;Cancer Innovation;2024-04

5. Pharmacological strategies for mitigating anti-TNF biologic immunogenicity in rheumatoid arthritis patients;Current Opinion in Pharmacology;2023-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3